Bleomycin Loaded Magnetite Nanoparticles Functionalized by Polyacrylic Acid as a New Antitumoral Drug Delivery System
Open Access
- 1 January 2013
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2013, 1-5
Abstract
Objective. To prepare, characterize, and analyze the release behavior of bleomycin-loaded magnetite nanoparticles (BLM-MNPs) coated with polyacrylic acid (PAA) as a new drug delivery system that can be specifically distributed in the tumor site.Methods. BLM-MNPs coated with PAA were prepared using a solvothermal approach. The particles were characterized using scanning electron microscope (SEM), vibrating sample magnetometer (VSM), and Fourier transform infrared spectroscopy (FTIR). The loading and release behaviors of BLM-MNPs were examined by a mathematical formula and in vitro release profile at pH 7.5.Results. The sphere Fe3O4nanoparticles with the size of approximately 30 nm exhibit a saturation magnetization of 87 emu/g. The noncoordinated carboxylate groups of PAA confer on the good dispersibility in the aqueous solution and lead to a good loading efficiency of BLM reaching 50% or higher. Approximately 98% of immobilized BLM could be released within 24 h, of which 22.4% was released in the first hour and then the remaining was released slowly and quantitatively in the next 23 hours.Conclusion. BLM-MNPs were prepared and characterized successfully. The particles show high saturation magnetization, high drug loading capacity, and favorable release property, which could contribute to the specific delivery and controllable release of BLM, and the BLM-MNPs could be a potential candidate for the development of treating solid tumors.Keywords
Funding Information
- Central Universities (11lgpy88, 09ykpy64, KF201145)
- Central Universities (11lgpy88, 09ykpy64, KF201145)
- Sun Yat-sen University (11lgpy88, 09ykpy64, KF201145)
This publication has 24 references indexed in Scilit:
- Bleomycin-Induced Raynaud's Phenomenon After Single-Dose Exposure: Risk Factors and Treatment With Intravenous Iloprost InfusionJournal of Clinical Oncology, 2013
- How to use bleomycin A5 for infantile maxillofacial haemangiomas: Clinical evaluation of 82 consecutive casesJournal of Cranio-Maxillofacial Surgery, 2011
- What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma?Critical Reviews in Oncology/Hematology, 2011
- Effect of inhaled KP-496, a novel dual antagonist of the cysteinyl leukotriene and thromboxane A2 receptors, on a bleomycin-induced pulmonary fibrosis model in micePulmonary Pharmacology & Therapeutics, 2010
- Preparation of pingyangmycin PLGA microspheres and related in vitro/in vivo studiesInternational Journal of Pharmaceutics, 2010
- Bleomycin Loaded Magnetic Chitosan Nanoparticles as Multifunctional NanocarriersJournal of Bioactive and Compatible Polymers, 2010
- Increased sensitivity to bleomycin in upper aerodigestive tract mucosa of head and neck squamous cell carcinoma patientsMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008
- The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?The International Journal of Biochemistry & Cell Biology, 2008
- Self assembled magnetic PVP/PVA hydrogel microspheres; magnetic drug targeting of VX2 auricular tumours using pingyangmycinJournal of Drug Targeting, 2006
- Bleomycin lung toxicity: who are the patients with increased risk?Pulmonary Pharmacology & Therapeutics, 2005